Literature DB >> 22372457

The epidemiology, pathogenesis and histopathology of fatty liver disease.

Adam P Levene1, Robert D Goldin.   

Abstract

Fatty liver disease includes non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD), each of which is increasing in prevalence. Each represents a histological spectrum that extends from isolated steatosis to steatohepatitis and cirrhosis. NAFLD is associated with obesity, diabetes, and insulin resistance, and is considered to be the liver manifestation of the metabolic syndrome. The pathogenesis of NAFLD and ALD involves cytokines, adipokines, oxidative stress, and apoptosis. Histopathology is the gold standard for assessing the severity of liver damage in NAFLD and ALD. We have reviewed the literature, and described and compared the epidemiology, natural disease history, pathogenesis and histopathology of NAFLD and ALD.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22372457     DOI: 10.1111/j.1365-2559.2011.04145.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  56 in total

Review 1.  Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Alexander Wree; Wajahat Z Mehal; Ariel E Feldstein
Journal:  Semin Liver Dis       Date:  2016-02-12       Impact factor: 6.115

Review 2.  Alcoholic liver disease: the gut microbiome and liver cross talk.

Authors:  Phillipp Hartmann; Caroline T Seebauer; Bernd Schnabl
Journal:  Alcohol Clin Exp Res       Date:  2015-05       Impact factor: 3.455

3.  Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.

Authors:  Srinevas K Reddy; Colleen Reilly; Min Zhan; Ayse L Mindikoglu; Yixing Jiang; Barton F Lane; H Richard Alexander; William J Culpepper; Samer S El-Kamary
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

4.  Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.

Authors:  Brett M McGettigan; Rachel H McMahan; Yuhuan Luo; Xiaoxin X Wang; David J Orlicky; Cara Porsche; Moshe Levi; Hugo R Rosen
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

5.  Association between circulating inflammatory molecules and alcoholic liver disease in men.

Authors:  Bao-Ge Qu; Weimin Bi; Yi-Guo Jia; Yuan-Xun Liu; Hui Wang; Ji-Liang Su; Li-Li Liu; Zhong-Dong Wang; Ya-Fei Wang; Xing-Hai Han; Jin-Dun Pan; Guang-Ying Ren; Wen-Juan Hu
Journal:  Cell Stress Chaperones       Date:  2016-06-21       Impact factor: 3.667

6.  The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease.

Authors:  Michael Georgoulis; Meropi D Kontogianni; Nafsika Tileli; Aikaterini Margariti; Elisabeth Fragopoulou; Dina Tiniakos; Rodessa Zafiropoulou; George Papatheodoridis
Journal:  Eur J Nutr       Date:  2014-03-07       Impact factor: 5.614

7.  NLRP3 inflammasome activation is required for fibrosis development in NAFLD.

Authors:  Alexander Wree; Matthew D McGeough; Carla A Peña; Martin Schlattjan; Hongying Li; Maria Eugenia Inzaugarat; Karen Messer; Ali Canbay; Hal M Hoffman; Ariel E Feldstein
Journal:  J Mol Med (Berl)       Date:  2014-05-28       Impact factor: 4.599

8.  Signal transducer and activator of transcriptions (STATs)-at the crossroads of obesity-linked non-alcoholic steatohepatitis and hepatocellular carcinoma.

Authors:  Nivida Mishra; Suresh Mishra
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

9.  Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery.

Authors:  Shinhiti Morita; Dalísio De Santi Neto; Flávio Hiroshi Ananias Morita; Nina Kimie Morita; Suzana Margareth Ajeje Lobo
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

Review 10.  Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner?

Authors:  Francesco Sofi; Alessandro Casini
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.